$13.68
0.29% yesterday
Nasdaq, Nov 21, 10:00 pm CET
ISIN
US30233G1004
Symbol
EYPT

EyePoint Pharmaceuticals, Inc. Stock price

$13.68
+1.87 15.83% 1M
+7.81 133.05% 6M
+6.23 83.62% YTD
+5.33 63.83% 1Y
+10.17 289.74% 3Y
+9.38 218.14% 5Y
-23.82 63.52% 10Y
-39.42 74.24% 20Y
Nasdaq, Closing price Fri, Nov 21 2025
+0.04 0.29%
ISIN
US30233G1004
Symbol
EYPT
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$928.5m
Net debt
positive
Cash
$204.0m
Shares outstanding
69.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
26.7 | 30.3
EV/Sales
21.9 | 24.8
EV/FCF
negative
P/B
5.7
Financial Health
Equity Ratio
80.4%
Return on Equity
-38.9%
ROCE
-98.5%
ROIC
-583.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$42.3m | $37.4m
EBITDA
$-216.3m | $-237.9m
EBIT
$-218.3m | $-231.7m
Net Income
$-205.8m | $-216.5m
Free Cash Flow
$-213.6m
Growth (TTM | estimate)
Revenue
-7.4% | -13.6%
EBITDA
-86.8% | -64.9%
EBIT
-86.7% | -58.9%
Net Income
-98.7% | -65.4%
Free Cash Flow
-81.0%
Margin (TTM | estimate)
Gross
94.1%
EBITDA
-510.8% | -636.6%
EBIT
-515.7%
Net
-486.0% | -579.3%
Free Cash Flow
-504.5%
More
EPS
$-2.9
FCF per Share
$-3.1
Short interest
10.6%
Employees
165
Rev per Employee
$260.0k
Show more

Is EyePoint Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

EyePoint Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from EyePoint Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
42 42
7% 7%
100%
- Direct Costs 2.51 2.51
35% 35%
6%
40 40
5% 5%
94%
- Selling and Administrative Expenses 57 57
8% 8%
134%
- Research and Development Expense 201 201
90% 90%
475%
-216 -216
87% 87%
-511%
- Depreciation and Amortization 2.08 2.08
75% 75%
5%
EBIT (Operating Income) EBIT -218 -218
87% 87%
-516%
Net Profit -206 -206
99% 99%
-486%

In millions USD.

Don't miss a Thing! We will send you all news about EyePoint Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EyePoint Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
3 days ago
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2026 with LUCIA data to closely follow – WATERTOWN, Mass., Nov. 19, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a compan...
Neutral
GlobeNewsWire
5 days ago
WATERTOWN, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in ...
Neutral
Seeking Alpha
16 days ago
EyePoint Pharmaceuticals, Inc. ( EYPT ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants George Elston - Executive VP & CFO Jay Duker - President, CEO & Director Ramiro Ribeiro - Chief Medical Officer Conference Call Participants Tessa Romero - JPMorgan Chase & Co, Research Division Yatin Suneja - Guggenheim Securities, LLC, Research Division Debanjana Chatterjee - JonesT...
More EyePoint Pharmaceuticals, Inc. News

Company Profile

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Duker
Employees 165
Founded 1987
Website eyepointpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today